Ara
Toplam kayıt 16, listelenen: 11-16
Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer
(Lippincott Williams & Wilkins, 2023)
...
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study
(Springer, 2023)
Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective ...
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
(Taylor and Francis Ltd., 2023)
To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ...
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...
Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
(Turkiye Klinikleri, 2023)
Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease ...